Preparations for the second EDCTP programme
On 6 May 2014, the Council of the European Union (EU) in its meeting on Economic and Financial Affairs (ECOFIN) approved the participation of the EU in the second phase of the EDCTP programme (EDCTP2), in accordance with the legislative proposal approved by the European Parliament on 15 April 2014. With this approval, the implementation phase of the second programme will start after signature of a delegation agreement between the European Commission (EC) and EDCTP, which is expected to take place in quarter 3/4 2014.
In the meantime, preparations are well underway for EDCTP2. On 10 April 2014, EDCTP changed its legal structure from a European Economic Interest Grouping (EEIG) to an Association under the Dutch law in order to enable sub-Saharan African countries to become full members of EDCTP, together with all countries associated to Horizon 2020, the EU Framework Programme for Research and Innovation. To date, nine sub-Saharan African countries have formalised their participation as Members of the EDCTP Association.
Call for proposals
EDCTP is in the process of preparing the EDCTP2 workplan for 2014-2015, which will outline the core activities and Calls for Proposals for the first two years of the programme. EDCTP2 will not officially launch any Calls for Proposals before the delegation agreement between the EC and EDCTP has been signed, but publication of the draft workplan is scheduled for quarter 3 2014.
It is anticipated that the Calls for Proposals for 2014-2015 will include broad topics in clinical research as well as various types of capacity support and fellowships.
EDCTP is in the process of implementing an online grants management system which is expected to be in place for the first EDCTP2 Calls for Proposals. More details on this system and guidelines for applicants will be available in due course.
Scope of EDCTP2
With an EU contribution of € 683 million for the 10-year programme period and additional contributions from Participating States and third parties, EDCTP2 will continue to support the clinical development of new or improved diagnostics, drugs, vaccines and microbicides against HIV/AIDS, tuberculosis, and malaria.
In addition, EDCTP2 will support research on neglected infectious diseases (NIDs), specifically dengue; rabies; human African trypanosomiasis (sleeping sickness); Leishmaniases; cysticercosis/taeniasis; dracunculiasis (guinea-worm disease); echinococcosis; foodborne trematodiases; lymphatic filariasis; onchocerciasis (river blindness); schistosomiasis; soil-transmitted helminthiases; Buruli ulcer; leprosy (Hansen disease); trachoma; yaws. From 2016, research on diarrhoeal and lower respiratory infections will also be supported.
All stages of clinical trials will be supported, from phase I to IV, though the main focus will be on phase II and III clinical trials.
EDCTP2 will continue to promote and support:
The geographical focus of EDCTP2’s activities will remain on sub-Saharan Africa, although collaborative research with other developing countries outside sub-Saharan Africa could be envisioned when possible and desirable.